Back to News
Feb 26, 2026 4:00 PM

Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients

Bristol Myers Squibb Co. (NYSE:BMY) shares are down on Thursday as the company releases positive interim results from a Phase 3 trial of izalontamab brengitecan (Iza-bren), in collaboration with SystImmune Inc.

This news comes as the broader market experienced mixed performance, with the Nasdaq slightly down while other indices showed modest gains.

Breast Cancer Trial Data

SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd., reported that Iza-bren met its dual primary endpoints of progression-free survival and overall survival in the interim analysis of the trial.

The trial patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease progressed following prior taxane therapy.

The update marks the third Phase 3 study where Iza-bren has achieved its primary endpoints, underscoring its potential in treating advanced triple-negative breast cancer.

The trial results indicate a statistically significant improvement in ...